Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report

Group 1: Acquisition Details - Sun Pharmaceutical Industries Ltd is evaluating a potential acquisition of Organon & Co, which could become the largest cross-border transaction by an Indian drugmaker, with a non-binding all-cash bid and $10–14 billion in acquisition financing arranged [1][2] - If completed, the transaction, valued at about $10 billion including debt, would be Sun Pharma's largest acquisition to date and significantly strengthen its presence in women's health biopharma and biosimilars [2][5] - Sun Pharma has engaged a European bank as an adviser to prepare a financial proposal for Organon's board, with talks still at a preliminary stage [3][4] Group 2: Organon's Financial Performance - Organon reported third-quarter adjusted earnings of $1.01 per share, exceeding the consensus of 94 cents, with sales up 1% to $1.60 billion, also beating the consensus of $1.58 billion [6] - The company lowered its fiscal 2025 sales guidance from $6.275 billion-$6.375 billion to $6.20 billion-$6.25 billion, which is below the consensus of $6.289 billion [6] Group 3: Organon's Debt and Recent Activities - Organon, spun off from Merck & Co. in 2021, has inherited debt of approximately $9.5 billion, which has been reduced to $8.9 billion as of the end of the second quarter of fiscal 2025 [3][4] - Recently, Organon acquired Dermavant for $1.2 billion and sold its JADA post-partum hemorrhage system for $465 million as part of its strategy to streamline its balance sheet [4] Group 4: Regulatory Approvals - The U.S. FDA approved a supplemental New Drug Application for Nexplanon, extending its duration of use from three years to five years, along with a new Risk Evaluation and Mitigation Strategy program [7][8]